Clinical trial · Interventional
Etoposide, Carboplatin, and Bleomycin in Treating Young Patients Undergoing Surgery For Malignant Germ Cell Tumors
Germ Cell Tumour Study II
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy, such as etoposide, carboplatin, and bleomycin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving chemotherapy drugs before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving combination chemotherapy after surgery may kill any tumor cells that remain. PURPOSE: This clinical trial is studying how well giving etoposide, carboplatin, and bleomycin works in treating young patients undergoing surgery for malignant germ cell tumors.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain and Central Nervous System Tumors | — | UNRESOLVED | — |
| Childhood Germ Cell Tumor | Childhood Germ Cell Tumor | ONTOLOGY_EXACT | 0.98 |
| Extragonadal Germ Cell Tumor | Extragonadal Germ Cell Tumor | ONTOLOGY_EXACT | 0.98 |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bleomycin sulfate | Biological | Bleomycin | ALIAS |
| carboplatin | Drug | Carboplatin | ALIAS |
| conventional surgery | Procedure | — | UNRESOLVED |
| etoposide | Drug | Etoposide | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 15 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically proven malignant germ cell tumors at all stages
* Testicular tumors
* Stage I - Confined to testes
* Stage II - Confined to testes and retroperitoneal/abdominal lymph nodes
* Stage III - Supradiaphragmatic nodal disease (mediastinal and/or supraclavicular)
* Stage IV - Extralymphatic spread (liver, lung, bone, brain, skin, etc.)
* Ovarian, uterine, vaginal, and sacrococcygeal tumors
* Stage I - Confined to ovary/uterus/vagina/pre- and postsacral area
* Stage II - Spread limited to the pelvis
* Stage III - Spread limited to the abdomen (excluding liver)
* Stage IV - Spread to liver or beyond the abdominal cavity
* Abdominal, retroperitoneal, and thoracic primary tumors
* Stage I - Confined to site of origin and resectable
* Stage II - Local spread
* Stage III - Extensive spread confined to one side of the diaphragm (excluding the liver)
* Stage IV - Tumor spread to the liver, to both sides of the diaphragm, and/or to bones, bone marrow, brain, etc.
* Intracranial germ cell tumor cases allowed even if an alternative protocol is being followed
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* No prior chemotherapyReferences
Publications (0)
Data not yet available